Three large healthcare companies — Pfizer, AbbVie, and Medtronic — are drawing attention from income investors in 2026. Each offers a dividend, but the similarities largely end there. Their business models, risks, and income profiles are quite different.
The healthcare sector carries real risks. Drug companies face patent expirations, pricing pressure, and clinical trial failures. Device makers deal with competition and hospital budget cycles. Despite those risks, aging populations and growing healthcare spending continue to support long-term demand.
Pfizer currently offers the highest dividend yield of the three, at around 6.7% annually. The company recently declared a second-quarter 2026 dividend of $0.43 per share, payable on June 12 to shareholders of record as of May 8.
That payment marks Pfizer’s 350th consecutive quarterly dividend. The annual dividend stands at $1.72 per share.
A yield that high is unusual for a major pharmaceutical company. It can signal that investors are uncertain about future growth, which is a fair concern given where Pfizer currently sits.
The company is still working through the fallout from its Covid-era revenue peak. It faces product-cycle challenges and upcoming patent expirations on key drugs. The business needs a credible turnaround story for the high yield to be sustainable long-term.
For investors who prioritize income and are comfortable with that risk, Pfizer stands out. For those who want more stability, the other two names may be a better fit.
AbbVie declared a quarterly dividend of $1.73 per share in February, payable on May 15, 2026. Its yield sits at around 3.2% to 3.3%, lower than Pfizer’s but still above many large-cap peers.
AbbVie built its business on Humira, which lost exclusivity to biosimilar competition. The key question for the company has been whether newer drugs could replace that revenue. So far, the answer looks encouraging. Its immunology drugs Skyrizi and Rinvoq have become major growth drivers. AbbVie also has exposure to neuroscience, oncology, and aesthetics.
That pipeline gives AbbVie a clearer growth story than a pure high-yield stock. The risk is execution — if newer drugs slow or pricing pressure increases, the business could face strain.
Medtronic takes a different approach entirely. It is a medical technology company, not a drugmaker. Its products cover cardiovascular care, diabetes, surgery, and neuroscience. This spreads its revenue across many treatment areas rather than depending on one drug.
The company’s standout feature is dividend consistency. Medtronic has raised its annual dividend for 48 consecutive years and is part of the S&P 500 Dividend Aristocrats index. Its current quarterly payment is $0.71 per share.
The yield is lower than Pfizer’s, but the track record is long. The main concern with Medtronic is growth, as investors have questioned whether its innovation pipeline can drive stronger returns over time.
Between the three, each company offers a distinct value proposition. Pfizer delivers the highest income but carries the most near-term uncertainty. AbbVie balances income with a developing growth story. Medtronic provides the most consistent dividend record in the group.
The post High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 appeared first on CoinCentral.
